Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual ...

Some six years after the FDA approved Eli Lilly’s Retevmo to treat lung and thyroid cancers that have a mutation or fusion to the RET gene, the Indianapolis drugmaker is laying groundwork to move the ...

Neoadjuvant chemoradiotherapy followed by surgery yielded similar 5-year overall survival rates compared to surgery and adjuvant therapy in patients with locally advanced esophageal squamous cell ...

A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely to benefit from PARP inhibitor cancer treatments, according to a study led ...

Please provide your email address to receive an email when new articles are posted on . Gaps in access remain, though, as almost half of patients did not receive next-generation sequencing. “These ...

Researchers at University of California San Diego School of Medicine have led the first clinical trial in the world to show that cancer drug treatments can be safely and effectively personalized based ...

A promising drug combination could help people with leukemia who don't respond to traditional treatments, according to new research. A team at Oregon Health and Science University made the discovery ...

Immunotherapy-based combinations have rapidly replaced tyrosine kinase inhibitors as first-line treatment for advanced hepatocellular carcinoma, reshaping real-world practice over the past decade. In ...

MAIA Biotechnology, Inc. ( (MAIA)) has shared an update. On December 10, 2025, MAIA Biotechnology announced a significant advancement in the treatment of advanced non-small cell lung cancer (NSCLC) ...

In July 2025, the FDA greenlit the use of sunvozertinib (Zegfrovy) for pretreated locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 ...

Experts discuss the complexities of treatment sequencing in cancer therapy, emphasizing the importance of using the best therapies upfront for optimal outcomes. Panelists discuss how sequencing ...